Support teaching, research, and patient care.
Jennifer Caswell-Jin, MD is an Assistant Professor of Medicine (Oncology) specializing in breast cancer care and research. She received her medical degree from Harvard Medical School in 2010, completed her internal medicine residency at the University of California, San Francisco in 2013, and completed her clinical fellowship in medical oncology at Stanford Hospital & Clinics in 2017. Her clinical translational research program is aimed at developing personalized approaches to care that improve the outcomes of people with breast cancer.
My research is on the translational application of next-generation sequencing technologies to breast cancer care: (1) the value of hereditary cancer genetic panel testing in clinical practice, (2) the mechanisms by which inherited genetic variants lead to breast cancer development, and (3) the analysis of somatic tumor sequencing data to inform understanding of breast tumorigenesis, metastasis, and development of resistance in response to therapeutics.
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and
cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and
antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor
View full details
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
The purpose of the study is identify the dose(s) of infigratinib to use in combination with
tamoxifen to treat patients with a particular type of advanced breast cancer (hormone
receptor-positive, HER2-negative, FGFR-altered breast cancer)
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Kody, 650-498-8583.